Periodicidade e escolha de exames laboratoriais na terapia hipolipemiante
| Autor: | Tania Leme da Rocha Martinez, HM Nascimento |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
chemistry.chemical_classification
medicine.medical_specialty business.industry Every Three Months Thyroid Plasma levels medicine.disease Gastroenterology chemistry.chemical_compound Enzyme medicine.anatomical_structure Nicotinic agonist chemistry Internal medicine Medicine Uric acid Lipid lowering Cardiology and Cardiovascular Medicine business Myositis |
| Zdroj: | Arquivos Brasileiros de Cardiologia. 85 |
| ISSN: | 0066-782X |
| DOI: | 10.1590/s0066-782x2005002400002 |
| Popis: | Pharmacologic lipid-lowering interventions should be monitored periodically to assess efficacy and safety parameters. Statins are usually well-tolerated drugs and major side effects include increased serum liver and muscle enzymes (AST, ALT, CK). Treatment should be stopped or diminished in case of significant increase of AST or ALT (> 3x ULN), or CK (> 10x ULN). Other lipid lowering agents may also produce hepatotoxicity or myositis, especially in association with statins (fibrates and nicotinic acid) or in presence of metabolic abnormalities (thyroid, liver or renal disorders). Nicotinic acid can also increase glucose and uric acid plasma levels. Laboratory tests might be performed prior to hypolipidemic drug treatment and should be repeated every three months during the first year and then at 6-mo intervals. Shorter intervals should be recommended in individual cases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|